West Pharmaceutical Services, Inc. (WST)
NYSE: WST · Real-Time Price · USD
209.13
0.00 (0.00%)
Apr 17, 2025, 4:00 PM EDT - Market closed
WST Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 2,893 | 2,950 | 2,887 | 2,832 | 2,147 | Upgrade
|
| Revenue Growth (YoY) | -1.92% | 2.18% | 1.95% | 31.89% | 16.69% | Upgrade
|
| Cost of Revenue | 1,895 | 1,820 | 1,751 | 1,654 | 1,379 | Upgrade
|
| Gross Profit | 998.5 | 1,130 | 1,136 | 1,178 | 767.8 | Upgrade
|
| Selling, General & Admin | 334.9 | 354.1 | 316 | 356.3 | 300.8 | Upgrade
|
| Research & Development | 69.1 | 68.4 | 58.5 | 52.8 | 46.9 | Upgrade
|
| Other Operating Expenses | 0.9 | 1.3 | -2.1 | - | -2.5 | Upgrade
|
| Operating Expenses | 404.9 | 423.8 | 372.4 | 409.1 | 345.2 | Upgrade
|
| Operating Income | 593.6 | 706.2 | 763.8 | 768.6 | 422.6 | Upgrade
|
| Interest Expense | -3 | -9 | -7.9 | -8.2 | -8.2 | Upgrade
|
| Interest & Investment Income | 19.6 | 28 | 5.1 | 1 | 1.4 | Upgrade
|
| Earnings From Equity Investments | 14.7 | 17.7 | 20.7 | 20.1 | 17.4 | Upgrade
|
| Currency Exchange Gain (Loss) | -10.2 | -9.4 | 4.1 | 1.4 | 1.5 | Upgrade
|
| EBT Excluding Unusual Items | 614.7 | 733.5 | 785.8 | 782.9 | 434.7 | Upgrade
|
| Merger & Restructuring Charges | -2.1 | 2 | -23.8 | -2.2 | -4.6 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.3 | -4.3 | -3.5 | -4.3 | -2.5 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -11.6 | - | - | - | Upgrade
|
| Asset Writedown | -7 | -5.3 | -2.7 | -4.1 | -7.7 | Upgrade
|
| Legal Settlements | - | 3.8 | - | - | - | Upgrade
|
| Other Unusual Items | -5.1 | -2.4 | -55.2 | -3.3 | -1.2 | Upgrade
|
| Pretax Income | 600.2 | 715.7 | 700.6 | 769 | 418.7 | Upgrade
|
| Income Tax Expense | 107.5 | 122.3 | 114.7 | 107.2 | 72.5 | Upgrade
|
| Net Income | 492.7 | 593.4 | 585.9 | 661.8 | 346.2 | Upgrade
|
| Net Income to Common | 492.7 | 593.4 | 585.9 | 661.8 | 346.2 | Upgrade
|
| Net Income Growth | -16.97% | 1.28% | -11.47% | 91.16% | 43.23% | Upgrade
|
| Shares Outstanding (Basic) | 73 | 74 | 74 | 74 | 74 | Upgrade
|
| Shares Outstanding (Diluted) | 74 | 75 | 76 | 76 | 76 | Upgrade
|
| Shares Change (YoY) | -2.13% | -0.66% | -0.66% | 0.66% | 0.53% | Upgrade
|
| EPS (Basic) | 6.75 | 7.99 | 7.88 | 8.90 | 4.68 | Upgrade
|
| EPS (Diluted) | 6.69 | 7.88 | 7.73 | 8.67 | 4.57 | Upgrade
|
| EPS Growth | -15.10% | 1.94% | -10.84% | 89.72% | 42.37% | Upgrade
|
| Free Cash Flow | 276.4 | 414.5 | 439.4 | 330.6 | 298.1 | Upgrade
|
| Free Cash Flow Per Share | 3.75 | 5.50 | 5.80 | 4.33 | 3.93 | Upgrade
|
| Dividend Per Share | 0.810 | 0.770 | 0.730 | 0.690 | 0.650 | Upgrade
|
| Dividend Growth | 5.20% | 5.48% | 5.80% | 6.15% | 6.56% | Upgrade
|
| Gross Margin | 34.51% | 38.31% | 39.36% | 41.59% | 35.76% | Upgrade
|
| Operating Margin | 20.52% | 23.94% | 26.46% | 27.14% | 19.68% | Upgrade
|
| Profit Margin | 17.03% | 20.12% | 20.29% | 23.37% | 16.13% | Upgrade
|
| Free Cash Flow Margin | 9.55% | 14.05% | 15.22% | 11.68% | 13.88% | Upgrade
|
| EBITDA | 749 | 843.5 | 884.4 | 890.9 | 531.7 | Upgrade
|
| EBITDA Margin | 25.89% | 28.59% | 30.64% | 31.46% | 24.77% | Upgrade
|
| D&A For EBITDA | 155.4 | 137.3 | 120.6 | 122.3 | 109.1 | Upgrade
|
| EBIT | 593.6 | 706.2 | 763.8 | 768.6 | 422.6 | Upgrade
|
| EBIT Margin | 20.52% | 23.94% | 26.46% | 27.14% | 19.68% | Upgrade
|
| Effective Tax Rate | 17.91% | 17.09% | 16.37% | 13.94% | 17.32% | Upgrade
|
Updated Feb 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.